阿加曲班在心脏骤停复苏中及链激酶在体外心肺复苏中的治疗作用:猪长时间心脏骤停模型
该研究为随机干预试验,48头猪经历8分钟室颤致心脏骤停、30分钟目标导向CPR及8小时ECPR,随机分四组(每组n=12):心脏骤停第12分钟给安慰剂或阿加曲班(350 mg/kg),ECPR启动时给安慰剂或链激酶(1.5 MU)。主要终点为心脏复苏评分(CRS,0-6分)和体感诱发电位(SSEP)皮层反应幅度恢复,组间均无显著差异(CRS p=0.16;SSEP p=0.73)。组织学分析显示阿加曲班+链激酶组较安慰剂+安慰剂组心肌坏死和神经变性减少。作者结论:该策略未改善心脑功能初期恢复,但减少缺血损伤的组织学证据,对长期恢复的影响需进一步研究。
要点
- 猪长时间心脏骤停ECPR模型中,阿加曲班(350 mg/kg,心脏骤停第12分钟)联合链激酶(1.5 MU,ECPR启动时)未改善心脏复苏评分(p=0.16)和SSEP皮层反应恢复(p=0.73)。
- 四组CRS分别为:安慰剂+安慰剂2.3(1.0)、阿加曲班+安慰剂3.4(2.1)、安慰剂+链激酶1.6(2.0)、阿加曲班+链激酶2.9(2.1),组间无显著差异。
- SSEP最大恢复相对基线:安慰剂+安慰剂23%(13%)、阿加曲班+安慰剂20%(13%)、安慰剂+链激酶25%(14%)、阿加曲班+链激酶26%(13%),组间无显著差异。
- 组织学分析显示阿加曲班+链激酶组较安慰剂+安慰剂组心肌坏死和神经变性减少。
- 作者结论:该策略未改善心脑功能初期恢复,但减少缺血损伤组织学证据;对长期功能恢复的影响需进一步研究。
适用人群与场景
- 猪长时间院外心脏骤停模型:8分钟室颤致心脏骤停,随后30分钟目标导向CPR和8小时ECPR。
处置流程与药物剂量
- 阿加曲班组:心脏骤停第12分钟给予阿加曲班350 mg/kg(原文单位如此)。
- 链激酶组:ECPR启动时给予链激酶1.5 MU。
研究设计与关键结果
- 研究类型:随机干预试验,盲法,48头猪,四组(每组n=12)。
- 干预:心脏骤停第12分钟给安慰剂或阿加曲班(350 mg/kg),ECPR启动时给安慰剂或链激酶(1.5 MU)。
- 主要终点心脏复苏评分(CRS,0-6分)组间无显著差异(p=0.16):安慰剂+安慰剂2.3(1.0),阿加曲班+安慰剂3.4(2.1),安慰剂+链激酶1.6(2.0),阿加曲班+链激酶2.9(2.1)。
- 主要终点SSEP皮层反应最大恢复相对基线组间无显著差异(p=0.73):安慰剂+安慰剂23%(13%),阿加曲班+安慰剂20%(13%),安慰剂+链激酶25%(14%),阿加曲班+链激酶26%(13%)。
- 组织学分析显示阿加曲班+链激酶组较安慰剂+安慰剂组心肌坏死和神经变性减少。
证据类型、等级与局限
- 证据类型:随机干预试验(猪模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在ECPR治疗的猪长时间心脏骤停模型中,目标导向CPR期间早期抗凝和ECPR期间溶栓未改善心脑功能初期恢复,但减少缺血损伤的组织学证据。
- 作者认为:该治疗策略对心血管和神经功能长期恢复的影响需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Prolonged cardiac arrest (CA) causes microvascular thrombosis which is a potential barrier to organ reperfusion during extracorporeal cardiopulmonary resuscitation (ECPR). The aim of this study was to test the hypothesis that early intra-arrest anticoagulation during cardiopulmonary resuscitation (CPR) and thrombolytic therapy during ECPR improve recovery of brain and heart function in a porcine model of prolonged out-of-hospital CA.
DESIGN: Randomized interventional trial.
SETTING: University laboratory.
INTERVENTIONS: In a blinded study, 48 swine were subjected to 8 minutes of ventricular fibrillation CA followed by 30 minutes of goal-directed CPR and 8 hours of ECPR. Animals were randomized into four groups (n = 12) and given either placebo (P) or argatroban (ARG; 350 mg/kg) at minute 12 of CA and either placebo (P) or streptokinase (STK, 1.5 MU) at the onset of ECPR.
MEASUREMENTS AND MAIN RESULTS: Primary outcomes included recovery of cardiac function measured by cardiac resuscitability score (CRS: range 0-6) and recovery of brain function measured by the recovery of somatosensory-evoked potential (SSEP) cortical response amplitude. There were no significant differences in recovery of cardiac function as measured by CRS between groups (p = 0.16): P + P 2.3 (1.0); ARG + P = 3.4 (2.1); P + STK = 1.6 (2.0); ARG + STK = 2.9 (2.1). There were no significant differences in the maximum recovery of SSEP cortical response relative to baseline between groups (p = 0.73): P + P = 23% (13%); ARG + P = 20% (13%); P + STK = 25% (14%); ARG + STK = 26% (13%). Histologic analysis demonstrated reduced myocardial necrosis and neurodegeneration in the ARG + STK group relative to the P + P group.
CONCLUSIONS: In this swine model of prolonged CA treated with ECPR, early intra-arrest anticoagulation during goal-directed CPR and thrombolytic therapy during ECPR did not improve initial recovery of heart and brain function but did reduce histologic evidence of ischemic injury. The impact of this therapeutic strategy on the long-term recovery of cardiovascular and neurological function requires further investigation.
参考来源
- VanZalen JJ, Harvey S, Hála P, et al. Therapeutic Effect of Argatroban During Cardiopulmonary Resuscitation and Streptokinase During Extracorporeal Cardiopulmonary Resuscitation in a Porcine Model of Prolonged Cardiac Arrest. Crit Care Explor. 2023. PMID: 37181541. doi:10.1097/CCE.0000000000000902
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。